Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Female Reproductive SystemDRG 737-uterine-and-adnexa-procedures-for-ovarian-or-adnexal-malignancy-with-cc
    Ask Trek AI about this page

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    DRG 737 encompasses uterine and adnexa procedures for ovarian or adnexal malignancy when a Complication or Comorbidity is documented, defining the clinical scope for inpatient reimbursement. This grouping matters because presence of a Complication or Comorbidity affects case classification and the Medicare inpatient payment for the hospital stay.

    Customize your policy alerts

    Sign up for drg 737 policy alerts

    Get alerted when payer policies referencing 737 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 737 Overview

    DRG 737 covers inpatient admissions for uterine and adnexa procedures performed for ovarian or adnexal malignancy when a Complication or Comorbidity is present. This Diagnosis-Related Group groups cases with similar clinical intensity and resource use to determine Medicare payment for the hospital stay. It matters for Medicare payment because the presence of a Complication or Comorbidity adjusts the relative weight and therefore the reimbursement amount for the inpatient episode. Typical cases include surgical management of ovarian or adnexal cancer with perioperative complications that increase resource consumption.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative multimodal therapy trials examining combinations of surgical cytoreduction with perioperative systemic chemotherapy or targeted agents: these studies enroll patients undergoing uterine and adnexa procedures for suspected ovarian or adnexal malignancy with comorbid complications (the CC component), and test timing or sequencing of systemic therapy (neoadjuvant vs immediate postoperative) and perioperative adjuncts to reduce tumor burden and complications. Research in this area addresses surgical morbidity and short-term recovery, helping providers optimize intraoperative decision-making and helping payers anticipate lengths of stay, ICU utilization, and bundled payment implications for high-acuity surgical admissions.
    • Comparative effectiveness studies of surgical approach and extent of resection in patients with ovarian or adnexal malignancy complicated by comorbid conditions: these observational or pragmatic randomized studies compare outcomes (perioperative complications, readmissions, need for reoperation) between minimally invasive, standard open laparotomy, and extended cytoreductive procedures specifically in patients with cardiorespiratory, metabolic, or other CC-level comorbidities. This research directly informs procedural choice for high-risk inpatients, supports guideline development for patient selection, and helps payers and hospitals evaluate resource use and expected complication-driven costs within this DRG.
    • Post-discharge outcomes and care coordination trials focusing on reducing readmissions and improving recovery after complex gynecologic oncology surgery: these interventional or cohort studies test discharge protocols, early outpatient surveillance, home-based supportive services, or enhanced recovery pathways tailored to patients with CC-level comorbidities following uterine and adnexa procedures. Results are relevant to providers aiming to lower postoperative complications and to payers interested in reducing 30-day readmissions, post-discharge costs, and variations in post-acute care utilization for this high-cost DRG.

    Related Codes

    734-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITH-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC: Inpatient Reimbursement Overview

    735-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITHOUT-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy: Inpatient Reimbursement Overview

    736-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    738-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    739-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    740-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    741-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    742-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITH-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy with CC/MCC: Inpatient Reimbursement Overview

    743-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy without CC/MCC: Inpatient Reimbursement Overview

    744-D-C-CONIZATION-LAPAROSCOPY-AND-TUBAL-INTERRUPTION-WITH-CC-MCC

    D&C, Conization, Laparoscopy and Tubal Interruption with CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.